CPI-169(CPI169)|EZH2 inhibitor|DC Chemicals

CPI-169(CPI169)|EZH2 inhibitor|DC Chemicals
CPI-169(R) is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apoptosis in a variety of cell lines.

Catlog: DC8155| Product name: CPI-169| Cas: 1450655-76-1| Other names: CPI-169,CPI 169,CPI169| Molecule Formula: C27H36N4O5S| MW: 528.66. Purity: >98%

Price: 100mg: 1100 USD; 250mg: 2000 USD; 1000mg: 3900 USD

CPI-169, a representative compound inhibits the catalytic activity of PRC2 with an IC50 of < 1nM, decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apoptosis in a variety of cell lines. Importantly, compound treatment triggers a sequence of downstream functional consequences of EZH2 inhibition whereby apoptosis is not induced before ten days of continuous target engagement.CPI-169 is well tolerated in mice with no observed toxic effect or body weight loss. In the present study we show that CPI-169 treatment led to tumor growth inhibition (TGI) of an EZH2 mutant KARPAS-422 DLBCL xenograft. The TGI is proportional to the dose administered and to the reduction of the pharmacodynamic marker H3K27me3. The highest dose, 200 mpk, BID led to complete tumor regression.

For research and scientific purpose only, not for human use.